

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-40 (cancelled)

Claim 41 (currently amended): The pharmaceutical composition of claim 40 70, wherein R is a straight chain alkyl having a chain length of C₇ to C₁₂, and W, X, Y, and Z are each hydrogen.

Claim 42 (original): The pharmaceutical composition of claim 41, wherein R is nonyl.

Claims 43-51 (cancelled).

Claim 52 (currently amended): The pharmaceutical composition of claim 43 70, wherein R is nonyl and W, X, Y, and Z are each butanoyl.

Claims 53-55 (cancelled).

Claim 56 (currently amended): The pharmaceutical composition of claim 70, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate, and said nucleoside antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

Claim 57 (original): The pharmaceutical composition of claim 56, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol.

Claim 58 (previously amended): The pharmaceutical composition of claim 70, wherein said first amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 0.1 mg to about 100 mg.


Claims 59-60 (cancelled).

Claim 61 (currently amended): The pharmaceutical composition of claim 70, wherein said second amount of said ~~nucleoside or nucleotide~~ antiviral compound, or mixture thereof, is in the range of from about 0.1 mg to about 500 mg.

Claims 62-68 (cancelled).

Claim 69 (original): A pharmaceutical composition for treating a hepatitis B virus infection in a human patient, comprising from about 0.1 mg to about 100 mg of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and from about 0.1 mg to about 500 mg of (-)-2'-deoxy-3'-thiacytidine-5' triphosphate.

Claim 70 (currently amended): A pharmaceutical composition for treating hepatitis virus infection, comprising a first amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



I

wherein:

R is selected from the group consisting of ~~arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having seven or more carbon atoms~~ a chain length of C₇ to C₁₂, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, ~~alkanoyl, aroyl, and trifluoroalkanoyl and butanoyl~~; and

a second amount of an antiviral compound selected from the group consisting of ~~a nucleoside antiviral compound, a nucleotide antiviral compound~~

2',3'-dideoxycytidine (ddC).

2',3'-dideoxycytidine-5'-triphosphate,

(-)2',3'-dideoxy-3'-thiacytidine,

(-)2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

and mixtures thereof, and

a pharmaceutically acceptable carrier, diluent, or excipient

wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.

Claims 71-75 (cancelled).